Clinical trials
System Lupus Erythematosus(SLE) clinical trials
Below are recruiting system lupus erythematosus(sle) clinical trials, each written for real people, not researchers. We’re tracking 216 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07056621Recruiting
How belimumab changes lupus over time
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
Athens, AtticaAges 18 years+ - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07041801RecruitingPhase 1/Phase 2
Stem cell therapy for lupus patients
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
Shenzhen, GuangdongAges 18–65 - NCT07043153Recruiting
Predicting lupus disease activity with blood tests
This study looks at whether two blood markers (AGR and PNI) can help track how active lupus is. You may be eligible if you have lupus and are not pregnant or have other serious health conditions.
SohagAges 18 years+ - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07011043RecruitingPhase 1
Study of budoprutug for lupus
This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.
Allen, TexasAges 18–65 - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06340750RecruitingPhase 1
BAFF CAR-T cells for lupus that hasn't improved with standard treatments
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
Columbus, OhioAges 18–65 - NCT06987565RecruitingPhase 2
Nerve stimulation device for lupus pain
This trial tests whether a non-invasive nerve stimulation device worn on the ear can help reduce pain and inflammation in people with lupus. It may be an option if you have moderate to severe muscle or joint pain and are not on certain medications that were recently started.
Manhasset, New YorkAges 18 years+ - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT06946485RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Nanjing, JiangsuAges 18–65 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06927219Recruiting
Lupus registry for patients and caregivers
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
Washington D.C., District of ColumbiaAges Any age - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for system lupus erythematosus(sle)?
- Yes. Clin2 currently lists 216 recruiting system lupus erythematosus(sle) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a system lupus erythematosus(sle) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a system lupus erythematosus(sle) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.